{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:25:37Z","timestamp":1789500337640,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Perinatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.semperi.2025.152045","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T09:23:52Z","timestamp":1741857832000},"page":"152045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune checkpoint inhibitors and pregnancy: Considerations for treating medically complex patients with the best available therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"Elad","family":"Sharon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semperi.2025.152045_bib0001","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00261-022-03633-y","article-title":"Cancer in pregnancy: overview and epidemiology","volume":"48","author":"Javitt","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"3","key":"10.1016\/j.semperi.2025.152045_bib0002","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2468-2667(18)30267-6","article-title":"Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry","volume":"4","author":"Sung","year":"2019","journal-title":"Lancet Public Health"},{"issue":"2","key":"10.1016\/j.semperi.2025.152045_bib0003","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-0040-1714394","article-title":"Cancer and pregnancy: national trends","volume":"39","author":"Ma","year":"2022","journal-title":"Am J Perinatol"},{"issue":"16","key":"10.1016\/j.semperi.2025.152045_bib0004","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMsb2300232","article-title":"Immune checkpoint inhibitors - the need for innovation","volume":"388","author":"Johnson","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.semperi.2025.152045_bib0005","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma","volume":"23","author":"Barone","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.semperi.2025.152045_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11912-020-0862-7","article-title":"Pregnancy and Cancer: the INCIP project","volume":"22","author":"Maggen","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.semperi.2025.152045_bib0007","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000456014","article-title":"Metastatic melanoma: treatment and survival in the US after the introduction of Ipilimumab and Vemurafenib","volume":"40","author":"Enewold","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"16","key":"10.1016\/j.semperi.2025.152045_bib0008","doi-asserted-by":"crossref","first-page":"e70131","DOI":"10.1002\/cam4.70131","article-title":"Evolving patterns in systemic treatment utilization and survival among older patients with advanced cutaneous melanoma","volume":"13","author":"Hong","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.semperi.2025.152045_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.semperi.2025.152045_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/CCO.0000000000001014","article-title":"Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence","volume":"36","author":"Benhima","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.semperi.2025.152045_bib0011","article-title":"Application and expectations for immune checkpoint blockade of LAG3 and TIGIT","author":"Dumbrava","year":"2024","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.semperi.2025.152045_bib0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semperi.2025.152045_bib0013","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.semperi.2025.152045_bib0014","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/ajh.26527","article-title":"Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma","volume":"97","author":"Evens","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.semperi.2025.152045_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010173","article-title":"Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase (\u00ae) spontaneous reporting System","volume":"15","author":"Noseda","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.semperi.2025.152045_bib0016","doi-asserted-by":"crossref","first-page":"e1883","DOI":"10.1002\/onco.13941","article-title":"Outcomes of pregnancy during immunotherapy treatment for Cancer: analysis of clinical trials sponsored by the National Cancer Institute","volume":"26","author":"Mittra","year":"2021","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.semperi.2025.152045_bib0017","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2308135","article-title":"Severe immune-related enteritis after In utero exposure to Pembrolizumab","volume":"389","author":"Baarslag","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semperi.2025.152045_bib0018","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following Immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.semperi.2025.152045_bib0019","doi-asserted-by":"crossref","first-page":"e950","DOI":"10.1093\/oncolo\/oyad135","article-title":"Evaluating survival after hospitalization due to immune-related adverse events from checkpoint inhibitors","volume":"28","author":"Silverstein","year":"2023","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.semperi.2025.152045_bib0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.semperi.2025.152045_bib0021","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with Immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.semperi.2025.152045_bib0022","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"}],"container-title":["Seminars in Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000525000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146000525000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:50:50Z","timestamp":1741881050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146000525000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0146000525000229"],"URL":"https:\/\/doi.org\/10.1016\/j.semperi.2025.152045","relation":{},"ISSN":["0146-0005"],"issn-type":[{"value":"0146-0005","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors and pregnancy: Considerations for treating medically complex patients with the best available therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Perinatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semperi.2025.152045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152045"}}